Does the media prefer PGEN or AUTL?

In the previous week, Autolus Therapeutics had 5 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Autolus Therapeutics and 2 mentions for Precigen. Precigen's average media sentiment score of 1.54 beat Autolus Therapeutics' score of 0.58 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Autolus Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AUTL or NKTR?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Nektar Therapeutics and 7 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.58 beat Nektar Therapeutics' score of 0.24 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUTL or VERA?

In the previous week, Vera Therapeutics had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 11 mentions for Vera Therapeutics and 7 mentions for Autolus Therapeutics. Vera Therapeutics' average media sentiment score of 1.35 beat Autolus Therapeutics' score of 0.58 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUTL or KOD?

In the previous week, Autolus Therapeutics had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.50 beat Autolus Therapeutics' score of 0.58 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or AUTL?

In the previous week, Autolus Therapeutics had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 7 mentions for Autolus Therapeutics and 4 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.63 beat Autolus Therapeutics' score of 0.58 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Autolus Therapeutics (AUTL) Competitors

$1.88 -0.08 (-4.08%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.91 +0.03 (+1.60%)

As of 09/11/2026 07:48 PM Eastern

Compare

AUTL vs. PGEN, NKTR, VERA, KOD, and NUVB

Should you buy Autolus Therapeutics stock or one of its competitors? Autolus Therapeutics's main competitors and comparable companies include Precigen (PGEN), Nektar Therapeutics (NKTR), Vera Therapeutics (VERA), Kodiak Sciences (KOD), and Nuvation Bio (NUVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Autolus Therapeutics compare to Precigen?

Precigen (NASDAQ:PGEN) and Autolus Therapeutics (NASDAQ:AUTL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Autolus Therapeutics had 5 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Autolus Therapeutics and 2 mentions for Precigen. Precigen's average media sentiment score of 1.54 beat Autolus Therapeutics' score of 0.58 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Autolus Therapeutics	0 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precigen has higher earnings, but lower revenue than Autolus Therapeutics. Precigen is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	252.28	-$250.64M	-$1.04	N/A
Autolus Therapeutics	$75.39M	6.64	-$287.53M	-$1.06	N/A

Precigen has a net margin of -183.98% compared to Autolus Therapeutics' net margin of -238.66%. Precigen's return on equity of 423.75% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Autolus Therapeutics	-238.66%	-178.66%	-49.34%

Precigen has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

33.5% of Precigen shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Precigen currently has a consensus target price of $14.50, suggesting a potential upside of 111.68%. Autolus Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 431.91%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Autolus Therapeutics beats Precigen on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Nektar Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Autolus Therapeutics has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Nektar Therapeutics had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Nektar Therapeutics and 7 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.58 beat Nektar Therapeutics' score of 0.24 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nektar Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.64	-$287.53M	-$1.06	N/A
Nektar Therapeutics	$55.23M	43.12	-$164.08M	-$6.70	N/A

Autolus Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 431.91%. Nektar Therapeutics has a consensus target price of $141.50, indicating a potential upside of 102.84%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Autolus Therapeutics has a net margin of -238.66% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Summary

Autolus Therapeutics beats Nektar Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Vera Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Autolus Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 431.91%. Vera Therapeutics has a consensus target price of $80.15, indicating a potential upside of 128.68%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Vera Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Vera Therapeutics' return on equity of -84.13% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Vera Therapeutics	N/A	-84.13%	-66.79%

Autolus Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Autolus Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.64	-$287.53M	-$1.06	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

In the previous week, Vera Therapeutics had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 11 mentions for Vera Therapeutics and 7 mentions for Autolus Therapeutics. Vera Therapeutics' average media sentiment score of 1.35 beat Autolus Therapeutics' score of 0.58 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Autolus Therapeutics beats Vera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Kodiak Sciences?

Autolus Therapeutics (NASDAQ:AUTL) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Kodiak Sciences has lower revenue, but higher earnings than Autolus Therapeutics. Kodiak Sciences is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.64	-$287.53M	-$1.06	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

Autolus Therapeutics has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Autolus Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 431.91%. Kodiak Sciences has a consensus target price of $48.14, indicating a potential upside of 46.38%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Kodiak Sciences has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Autolus Therapeutics' return on equity of -178.66% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Kodiak Sciences	N/A	-273.23%	-85.48%

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Autolus Therapeutics had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.50 beat Autolus Therapeutics' score of 0.58 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Autolus Therapeutics beats Kodiak Sciences on 9 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Autolus Therapeutics (NASDAQ:AUTL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nuvation Bio has higher earnings, but lower revenue than Autolus Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	34.08	-$204.63M	-$0.44	N/A
Autolus Therapeutics	$75.39M	6.64	-$287.53M	-$1.06	N/A

Nuvation Bio currently has a consensus target price of $13.00, suggesting a potential upside of 112.94%. Autolus Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 431.91%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Nuvation Bio has a net margin of -88.18% compared to Autolus Therapeutics' net margin of -238.66%. Nuvation Bio's return on equity of -46.59% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Autolus Therapeutics	-238.66%	-178.66%	-49.34%

In the previous week, Autolus Therapeutics had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 7 mentions for Autolus Therapeutics and 4 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.63 beat Autolus Therapeutics' score of 0.58 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autolus Therapeutics	0 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

Summary

Nuvation Bio beats Autolus Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$500.39M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-1.77	14.18	274.94	25.36
Price / Sales	6.64	1,374.96	685.44	117.05
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	2.81	15.12	10.33	6.20
Net Income	-$287.53M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-16.07%	-4.34%	-3.32%	-2.35%
1 Month Performance	-15.32%	0.54%	-0.53%	-3.23%
1 Year Performance	36.23%	40.74%	23.51%	8.79%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	3.9022 of 5 stars	$1.88 -4.1%	$10.00 +431.9%	+36.2%	$500.39M	$75.39M	N/A	330
PGEN Precigen	3.9797 of 5 stars	$6.93 -0.3%	$14.50 +109.2%	+80.7%	$2.48B	$9.68M	N/A	190	Positive News
NKTR Nektar Therapeutics	2.5981 of 5 stars	$71.38 -1.6%	$141.50 +98.2%	+43.3%	$2.48B	$55.23M	N/A	220	Analyst Forecast
VERA Vera Therapeutics	3.0952 of 5 stars	$34.08 -0.3%	$81.15 +138.1%	+47.5%	$2.46B	N/A	N/A	40	News Coverage Positive News Analyst Forecast
KOD Kodiak Sciences	2.1222 of 5 stars	$37.35 -1.0%	$48.14 +28.9%	+255.6%	$2.37B	N/A	N/A	90	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. PGEN, NKTR, VERA, KOD, and NUVB

How does Autolus Therapeutics compare to Precigen?

Summary

How does Autolus Therapeutics compare to Nektar Therapeutics?

Summary

How does Autolus Therapeutics compare to Vera Therapeutics?

Summary

How does Autolus Therapeutics compare to Kodiak Sciences?

Summary

How does Autolus Therapeutics compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. PGEN, NKTR, VERA, KOD, and NUVB

How does Autolus Therapeutics compare to Precigen?

Does the media prefer PGEN or AUTL?

Which has stronger valuation & earnings, PGEN or AUTL?

Is PGEN or AUTL more profitable?

Which has more risk & volatility, PGEN or AUTL?

Do institutionals & insiders believe in PGEN or AUTL?

Do analysts prefer PGEN or AUTL?

Summary

How does Autolus Therapeutics compare to Nektar Therapeutics?

Which has more risk and volatility, AUTL or NKTR?

Do insiders and institutionals believe in AUTL or NKTR?

Does the media refer more to AUTL or NKTR?

Which has stronger earnings & valuation, AUTL or NKTR?

Do analysts prefer AUTL or NKTR?

Is AUTL or NKTR more profitable?

Summary

How does Autolus Therapeutics compare to Vera Therapeutics?

Do analysts rate AUTL or VERA?

Is AUTL or VERA more profitable?

Which has more volatility & risk, AUTL or VERA?

Do institutionals and insiders believe in AUTL or VERA?

Which has better earnings and valuation, AUTL or VERA?

Does the media favor AUTL or VERA?

Summary

How does Autolus Therapeutics compare to Kodiak Sciences?

Which has better earnings and valuation, AUTL or KOD?

Which has more volatility & risk, AUTL or KOD?

Do analysts recommend AUTL or KOD?

Is AUTL or KOD more profitable?

Do insiders and institutionals have more ownership in AUTL or KOD?

Does the media favor AUTL or KOD?

Summary

How does Autolus Therapeutics compare to Nuvation Bio?

Do institutionals & insiders believe in NUVB or AUTL?

Which has stronger earnings and valuation, NUVB or AUTL?

Do analysts prefer NUVB or AUTL?

Is NUVB or AUTL more profitable?

Does the media refer more to NUVB or AUTL?

Which has more volatility & risk, NUVB or AUTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools